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A B S T R A C T
Background: New nodules are regularly found after the baseline round of low-dose computed tomography
(LDCT) lung cancer screening. The relationship between a participant’s number of new nodules and lung cancer
probability is unknown.
Methods: Participants of the ongoing Dutch-Belgian Randomized Lung Cancer Screening (NELSON) Trial with
(sub)solid nodules detected after baseline and registered as new by the NELSON radiologists were included. The
correlation between a participant’s new nodule count and the largest new nodule size was assessed using
Spearman's rank correlation. To evaluate the new nodule count as predictor for new nodule lung cancer together
with largest new nodule size, a multivariable logistic regression analysis was performed.
Results: In total, 705 participants with 964 new nodules were included. In 48% (336/705) of participants no
nodule had been found previously during baseline screening and in 22% (154/705) of participants> 1 new
nodule was detected (range 1–12 new nodules). Eventually, 9% (65/705) of the participants had lung cancer in a
new nodule. In 100% (65/65) of participants with new nodule lung cancer, the lung cancer was the largest or
only new nodule at initial detection. The new nodule lung cancer probability did not diﬀer signiﬁcantly between
participants with 1 (10% [56/551], 95%CI 8–13%) or> 1 new nodule (6% [9/154], 95%CI 3–11%, P= .116).
An increased number of new nodules positively correlated with a participant’s largest nodule size (P < 0.001,
Spearman’s rho 0.177). When adjusted for largest new nodule size, the new nodule count had a signiﬁcant
negative association with lung cancer (odds ratio 0.59, 0.37–0.95, P= .03).
Conclusion: A participant’s new nodule count alone only has limited association with lung cancer. However, a
higher new nodule count correlates with an increased largest new nodule size, while the lung cancer probability
remains equivalent, and may improve lung cancer risk prediction by size only.
1. Introduction
Lung cancer screening using low-dose computed tomography
(LDCT) is currently recommended by US guidelines for high-risk in-
dividuals [1–3], after the National Lung Screening Trial reported a 20%
reduced lung cancer mortality for LDCT compared to chest radiography
screening [4]. Lung nodules are common ﬁndings in LDCT lung cancer
screening. European and American trials with no or very low detection
limits reported a noncalciﬁed lung nodule prevalence in 41–51% of
participants at baseline screening [5–9]. Since most detected nodules
are benign, the eﬀective identiﬁcation of potentially malignant nodules
is central to current lung cancer screening programs. While nodule
management is mainly based on size and growth [10,11], other nodule
characteristics, such as nodule morphology or nodule location, have
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traditionally been associated with an increased probability for lung
cancer [10–13]. Furthermore, patient characteristics such as age or
smoking pack-years play a crucial role in identifying high-risk in-
dividuals eligible for screening [8,12,14].
However, within a lung cancer screening program, but also in reg-
ular clinical practice, individuals may be diagnosed with several no-
dules at baseline or at follow-up screening [5–9,12,13]. There are only
limited data concerning the relationship of the number of nodules de-
tected in a participant (or nodule count) and lung cancer probability.
For nodules detected at baseline screening, a recent analysis of the
largest European lung cancer screening trial indicated that the baseline
nodule count alone does not predict lung cancer [15]. On nodule level,
one large study indicated a negative association between the nodule
count and a baseline nodule’s lung cancer probability when assessed
together with other known risk-factors, also reﬂecting the low in-
cidence of double malignancies [12].
During a lung cancer screening program, annually in 3–13% of
participants new nodules are detected that were not present at baseline
screening [5,16–19]. Recently, it was shown that new nodules carry a
higher lung cancer probability at smaller size than do baseline nodules
[19]. However, an array of non-malignant diseases may be associated
with the development of new lung nodules and some participants may
tend to develop multiple benign lung nodules of varying size [9,20].
The appropriate risk-stratiﬁcation of new nodules is important to a lung
cancer screening program, as they account for a signiﬁcant proportion
of lung cancers found after the baseline round [19,21,22]. Till recently
most research focused on nodules detected at baseline screening and
there is only limited evidence on the management of new nodules
[1,11,19]. In a current European position statement on lung cancer
screening, it was stressed that the management of new nodules should
be diﬀerent from baseline nodules since they have a higher pretest
probability which was also adopted in the British Thoracic Society
Guidelines for the Investigation and Management of Pulmonary No-
dules [22]. At present, there is no evidence regarding an association of
the new nodule count after baseline lung cancer screening and the
development of new nodule lung cancer. Aim of this study was to assess
the relationship of a participant’s number of new nodules and the new
nodule lung cancer probability, using data from the largest European
randomized controlled lung cancer screening trial.
2. Material and methods
2.1. Study population
The Dutch-Belgian Randomized Lung Cancer Screening (acronym
NELSON, trial registration number: ISRCTN63545820) trial’s study
design and recruitment process have been published previously
[7,23,24]. Brieﬂy, (ex-) smokers aged 50–75, who had smoked at least
15 cigarettes daily for 25 years or 10 cigarettes daily for 30 years and
were still smoking or stopped smoking less than 10 years ago were
eligible. The Ethics committees of all participating centers approved the
NELSON trial. All participants provided their written informed consent.
Between April 2004 and December 2006, 7557 participants underwent
baseline screening. The subsequent incidence screening rounds took
place 1 year, 3 years, and 5.5 years after baseline screening. The current
study included participants in whom the NELSON radiologists regis-
tered a new noncalciﬁed nodule during the three incidence screening
rounds.
2.2. CT scanning protocol and image reading
Low-dose CT scans were performed at one of four screening sites
using 16-MDCT scanners or 64-MDCT scanners (Sensation-16, Siemens
Medical Solutions, Forchheim, Germany; or Mx8000 IDT or Brilliance
16P, Philips Medical Systems, Best, Netherlands). Depending on the
participant’s body weight (< 50 kg, 50–80 kg, or> 80 kg), low-dose
settings (80–90 kVp, 120 kVp, and 140 kVp) were adapted to match a
dose index volume of 0.8mGy, 1.6mGy, or 3.2 mGy respectively.
Datasets were derived from images of the thorax with 1.0mm slice
width and a 0.7mm reconstruction interval. The data acquisition and
imagining protocols were standard across screening sites [7,23]. CT-
image analysis occurred on digital workstations (Leonardo, Siemens
Medical Solutions) which enabled semiautomated volume analysis
using software (LungCare, version Somaris/5 VA70C-W, Siemens
Medical Solutions). Image reading was performed by two independent
radiologists in the ﬁrst two rounds and by one radiologist in the third
and fourth round, after it was demonstrated that reading consensus
provides no beneﬁt with the use of semiautomated software [25]. In
case of high suspicion of malignancy (eg, enlarged mediastinal lymph
nodes) or benignity (eg, benign calciﬁcation patterns), radiologist could
overrule protocol-based screening results (as done for 195 [6%] of 3318
participants at the baseline screening round) and adjust the nodule
volume in case of inappropriate segmentation [26]. Detected nodules
were matched to previous scans by the software’s algorithm and
matching was visually conﬁrmed by the radiologist. Data generated
during CT evaluation were immediately uploaded to the NELSON
management system (10). This study included data and measurements
as uploaded to the NELSON management system and no new or repeat
measurements were performed. Nodules were considered new if labeled
as new and not present on previous scans by the NELSON radiologists.
2.3. Nodule management protocol
The detailed NELSON nodule management protocol was published
previously [23]. At ﬁrst detection, new nodules were classiﬁed into four
categories according to their size and characteristics (NODCAT I–IV).
Calciﬁed nodules and nodules with other benign characteristics were
considered benign (NODCAT I). New solid nodules measuring
15–50mm3 and new subsolid nodules with diameter 4–8mm (NODCAT
II, follow-up LDCT within one year) as well as new solid nodules
50–500mm3 and new subsolid nodules≥8mm (NODCAT III, follow up
LDCT within six-eight weeks) were considered indeterminate, requiring
nodule growth assessment. New solid nodules≥500mm3 (NODCAT IV,
immediate referral to pulmonologist) were considered positive.
2.4. Outcomes
A nodule was classiﬁed as lung cancer when it was diagnosed as
lung cancer during diagnostic workup according to national and in-
ternational guidelines including histologic examination [23]. Nodules
were classiﬁed as benign when either: (a) the nodule was benign at
histologic examination; (b) extensive workup by a pulmonologist, in-
cluding contrast material–enhanced CT, PET, and bronchial washing,
had a negative ﬁnding; (c) the nodule was ruled negative during the
participant’s last follow-up in the NELSON trial. As far as accessible in
this ongoing trial, data was linked with the Dutch and Belgian national
cancer registries and medical ﬁles reviewed concerning the occurrence
of post-screening lung cancer (completed for the second and third in-
cidence screening round) [21,23,27].
2.5. Nodule counts
For this study two nodule counts were calculated for each partici-
pant. First, the number of new noncalciﬁed nodules detected simulta-
neously at a participant’s ﬁrst new nodule detection after baseline and
second, the number of noncalciﬁed nodules detected at baseline
screening. The new nodule count may reﬂect the presence of non-ma-
lignant disease. The baseline nodule count might also reﬂect a parti-
cipant’s tendency to develop nodules.
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2.6. Statistical analysis
Normality of continuous variables was evaluated through the
Kolmogorov–Smirnov test and visual assessment. All included con-
tinuous variables were non-normally distributed and are presented as
median and interquartile range (IQR). Categorical variables are shown
as frequencies and respective percentages. The Agresti-Coull method
was used to calculate 95% conﬁdence intervals (95%CI) of proportions.
The correlation of the participant’s new nodule count and the partici-
pant’s age at baseline, the smoking pack-years at baseline, the volume
of the largest nodule and the volume of all new nodules was assessed
using Spearman’s rank correlation. Categorical variables stratiﬁed by
the new nodule count (0, 1, 2, 3, 4, ≥5) were assessed using Fisher’s
exact test or the χ2 test as appropriate. The Mann–Whitney U test was
used for comparison of nodule volume between two groups. The dis-
criminative performance of the nodule count with new nodule lung
cancer as outcome was evaluated through construction of the area
under the receiver-operating-characteristic curve (AUC). To evaluate
new nodule count as predictor for new nodule lung cancer together
with largest new nodule size (i.e. one case per participant), multi-
variable logistic regression analysis was performed including new no-
dule count and size (highest new nodule NODCAT classiﬁcation and
largest new solid nodule volume respectively). In participants where
the largest new nodule could not be established based on the exact
volume measurement (1% [10/705]), the nodule with the highest
NODCAT classiﬁcation was considered largest. The model calibration
was assessed by a Hosmer-Lemeshow goodness-of-ﬁt test and through
comparison of observed and predicted probabilities. Statistical analyses
were performed with SPSS version 24.0 (IBM, Armonk, NY, USA),
Medcalc version 17.1 (Medcalc Software, Mariakerke, Belgium), and
Microsoft Excel (Microsoft Corporation, Redmond, WA, USA).
3. Results
In total, 705 participants with 964 new nodules were included
(Fig. 1). Participant characteristics are presented in Table 1. Median
participant age at baseline was 59 years (IQR 55–63 years) and 79%
(558/705) of participants were male. Subsolid new nodules were de-
tected in 6% (49/705) of participants and 5% (3/65) of the new nodule
lung cancers were found in subsolid lesions. In 48% (336/705) of
participants no nodule had been found previously during baseline
screening and in 22% (154/705) of participants> 1 new nodule was
detected (range 1–12 new nodules). Eventually, 9% (65/705) of the
participants were diagnosed with lung cancer in one of the detected
new nodules. In all participants with new nodule lung cancer, the lar-
gest (14% [9/65]) or only (86% [56/65]) new nodule was diagnosed as
lung cancer.
On participant level, receiver operating curve analysis demon-
strated no signiﬁcant predictive ability of the new nodule count for lung
cancer (AUC 0.55, 95%CI 0.48–0.62). A participant’s overall new no-
dule lung cancer probability did not signiﬁcantly diﬀer between par-
ticipants with 1 new nodule (10% [56/551], 95%CI 8–13%) or> 1 new
nodule (6% [9/154], 95%CI 3–11%, P= .116). Participants with
multiple new nodules that clustered in one lung lobe had a lower but
not statistically diﬀerent lung cancer frequency when compared to
participants with multiple new nodules but no clustering (2% [1/44]
vs. 7% [8/110), P= .232. On nodule level, a lower number of si-
multaneously detected new nodules showed a moderate predictive
ability for lung cancer (AUC 0.67, 95%CI 0.61–0.72) with no double
cancers being detected. The participant’s nodule count at baseline
screening demonstrated no signiﬁcant discriminative performance for
new nodule lung cancer, neither participant level (AUC 0.52, 95%CI
0.45–0.59) nor nodule level (AUC 0.53, 95%CI 0.46–0.60).
The nodule size and lung cancer probability stratiﬁed by the parti-
cipant’s number of new nodules are shown in Table 2. While the median
volume of the participant’s largest nodule increased signiﬁcantly with
more new nodules detected (P < 0.001, Spearman’s rho 0.177), the
lung cancer probability remained equivalent (P= .63). The lung cancer
probability of participants in whom the only detected new nodule was
NODCAT III or IV was signiﬁcantly higher compared to participants
with NODCAT III or IV nodules but> 1 new nodule detected (15% [50/
333], 95%CI 12–19% vs. 8% [9/119], 95%CI 4–14%, P= .04). When
adjusted for the size of the largest new (solid) nodule (Table 3), the new
nodule count was a signiﬁcant predictor, having a negative association
with new nodule lung cancer.
4. Discussion
This analysis focused on participants with new nodules detected
during the three incidence rounds of the NELSON trial. We assessed the
relationship between the number of new nodules detected in a parti-
cipant and the probability of developing lung cancer in a new nodule.
There are ﬁve major ﬁndings. First, in 22% (154/705) of partici-
pants more than one new nodule was detected at initial new nodule
detection. Second, the lung cancer probability, did not diﬀer sig-
niﬁcantly between participants with one and more than one new no-
dule. Third, an increased number of new nodules was correlated with a
greater largest new nodule size. Fourth, the new nodule count had a
signiﬁcant negative association with new nodule lung cancer when
assessed together with nodule size. Fifth, the participant’s overall no-
dule count at baseline screening was not signiﬁcantly associated with
new nodule lung cancer.
To our knowledge, this is the ﬁrst study providing evidence con-
cerning a possible impact of a participant’s nodule count and the lung
cancer probability in new solid nodules. Lung cancer screening parti-
cipants only have one baseline screen, but potentially many incidence
screenings and with increasing duration, a program’s success depends
on the management of new nodules. Contrary to baseline nodules,
which may have been present for years, new nodules develop in a
known timeframe and comprise a group of comparably young nodules
[19]. A study focusing on the development of a lung cancer risk model
for baseline nodules reported a reduced lung cancer probability with an
increasing number of baseline nodules [12]. The ﬁndings of this study
show similar results for new nodules on nodule level. Nevertheless, on
participant level the new nodule count alone showed limited dis-
criminative performance for new nodule lung cancer (AUC 0.55, 95%CI
0.48–0.62). This is comparable to a recent analysis of the NELSON
baseline round, where baseline lung cancer probability did not diﬀer
signiﬁcantly per baseline nodule count [15]. However, the here pre-
sented ﬁndings indicate that in combination with new nodule size the
new nodule count has a signiﬁcant negative association with new no-
dule lung cancer. This may be explained through the observation that
an increased new nodule count is associated with a greater size of the
largest nodule found in a participant, while the lung cancer probability
remains at least equivalent.
At initial nodule detection and before growth assessment is feasible,
nodule size is the most important predictor for lung cancer in both
baseline and new nodules and is used for risk-stratiﬁcation in present
guidelines [10,11,19,22]. Currently, the management of detected no-
dules in lung cancer screening and clinical practice, focusses on the
most suspicious or typically largest nodule detected [10,11,19,22]. This
reﬂects a participant-based approach with a theoretical lung cancer
probability of smaller nodules not taken into account. The ﬁndings of
this study show that factoring in the new nodule count could adapt a
participant’s lung cancer risk stratiﬁcation in a multivariate approach
that includes the largest nodule size. However, additional data is
needed to conﬁrm these ﬁndings and assess new nodule count together
with other risk factors.
This study has limitations. The NELSON trial’s detection limit was
15mm3 and smaller new nodules could not be considered in this ana-
lysis. However, newly detected nodules above 15mm3 and visible
below the studies detection limit on a previous scan were excluded.
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Further, the expertise of radiologist was shown to decrease false-posi-
tive screening results [26]. Radiologists potentially increased their ex-
pertise in distinguishing scars or infections from suspicious lesions
during the trial and could have refrained from classifying them as
suspicious nodules to avoid false-positive results. We cannot exclude
the possibility that the actual number of new nodules is slightly higher
than reported in the NELSON management system. Within the NELSON
management protocol, larger nodules potentially received an additional
follow-up LDCT or were referred for further diagnostic work-up. To
minimize bias through the protocol, this analysis incorporated all
follow-up data of a nodule within the NELSON trial including cancer
diagnosis in later rounds and information from the national cancer re-
gistries concerning post-screening lung cancer.
5. Conclusion
In around one-ﬁfth of participants with new nodules in incidence
lung cancer screening rounds, more than one new nodule is present. A
participant’s number of new nodules alone only provides limited dis-
criminatory information for new nodule lung cancer probability.
However, with an increasing number of new nodules, the largest new
nodule tends to be bigger, while the participant’s overall new nodule
lung cancer probability remains equivalent. Therefore, relating the
largest new nodule size with the number of new nodules found could
adjust a participant’s lung cancer risk based on the largest nodule size
only.
997 par??ipants with 1,563 non?al?i?ed new (sub)solid 
nodules dete?ted in the three in?iden?e s?reening rounds 
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Fig. 1. Flowchart of participants and new nodules included in the analysis.
Table 1
Participant characteristics stratiﬁed by number of new nodules detected.
All participants Number of new nodules detected simultaneously in a participant P-Value
1 2 3 4 ≥5
Number of participants (%) 705 (100) 551 (78) 99 (14) 31 (4) 13 (2) 11 (2)
Male sex (%) 558/705 (79) 442/551 (80) 72/99 (73) 23/31 (74) 12/13 (92) 9/11 (82) 0.334
Age at baseline
Median 59 59 59 58 62 61 0.794
IQR 55–63 55–63 55–62 54–65 57–66 57–72
Pack-years at baseline
Median 39 39 39 44 49 34 0.455
IQR 30–53 30–53 30–49 38–56 27–58 31–38
New subsolid nodule (%) 49/705 (6) 35/551 (6) 8/99 (8) 2/31 (6) 1/13 (8) 3/11 (27) 0.131
Abbreviations: IQR – Interquartile range.
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